These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 34833268)

  • 1. Chelators for Treatment of Iron and Copper Overload: Shift from Low-Molecular-Weight Compounds to Polymers.
    Hruby M; Martínez IIS; Stephan H; Pouckova P; Benes J; Stepanek P
    Polymers (Basel); 2021 Nov; 13(22):. PubMed ID: 34833268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hereditary Liver Diseases: Wilson's Disease and Hemochromatosis].
    Merle U; Mohr I
    Dtsch Med Wochenschr; 2023 Jul; 148(13):836-843. PubMed ID: 37364578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and future therapy in haemochromatosis and Wilson's disease.
    Murray KF; Lam D; Kowdley KV
    Expert Opin Pharmacother; 2003 Dec; 4(12):2239-51. PubMed ID: 14640923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hereditary iron and copper deposition: diagnostics, pathogenesis and therapeutics.
    Aaseth J; Flaten TP; Andersen O
    Scand J Gastroenterol; 2007 Jun; 42(6):673-81. PubMed ID: 17505988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biopolymer strategy for the treatment of Wilson's disease.
    Vetrik M; Mattova J; Mackova H; Kucka J; Pouckova P; Kukackova O; Brus J; Eigner-Henke S; Sedlacek O; Sefc L; Stepanek P; Hruby M
    J Control Release; 2018 Mar; 273():131-138. PubMed ID: 29407674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus and Alzheimer's disease.
    Cooper GJ
    Drugs; 2011 Jul; 71(10):1281-320. PubMed ID: 21770477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Metabolism of iron and copper, action of chelators and therapeutic possibilities in Wilson's disease and hemochromatosis].
    PIRART J
    Pathol Biol; 1961 May; 9():1157-74. PubMed ID: 13735975
    [No Abstract]   [Full Text] [Related]  

  • 8. Chelating mitochondrial iron and copper: Recipes, pitfalls and promise.
    Lamačová LJ; Trnka J
    Mitochondrion; 2024 Sep; 78():101903. PubMed ID: 38777220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The onset of psychiatric disorders and Wilson's disease].
    Benhamla T; Tirouche YD; Abaoub-Germain A; Theodore F
    Encephale; 2007 Dec; 33(6):924-32. PubMed ID: 18789784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron accumulation in the liver of male patients with Wilson's disease.
    Shiono Y; Wakusawa S; Hayashi H; Takikawa T; Yano M; Okada T; Mabuchi H; Kono S; Miyajima H
    Am J Gastroenterol; 2001 Nov; 96(11):3147-51. PubMed ID: 11721763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chelating Polymers for Hereditary Hemochromatosis Treatment.
    Groborz O; Poláková L; Kolouchová K; Švec P; Loukotová L; Miriyala VM; Francová P; Kučka J; Krijt J; Páral P; Báječný M; Heizer T; Pohl R; Dunlop D; Czernek J; Šefc L; Beneš J; Štěpánek P; Hobza P; Hrubý M
    Macromol Biosci; 2020 Dec; 20(12):e2000254. PubMed ID: 32954629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chelating polymeric beads as potential therapeutics for Wilson's disease.
    Mattová J; Poučková P; Kučka J; Skodová M; Vetrík M; Stěpánek P; Urbánek P; Petřík M; Nový Z; Hrubý M
    Eur J Pharm Sci; 2014 Oct; 62():1-7. PubMed ID: 24815561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paradigm shift in treatment of Wilson's disease: zinc therapy now treatment of choice.
    Hoogenraad TU
    Brain Dev; 2006 Apr; 28(3):141-6. PubMed ID: 16466879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of iron and copper overload on the human liver: an ultrastructural study.
    Fanni D; Fanos V; Gerosa C; Piras M; Dessi A; Atzei A; Van EP; Gibo Y; Faa G
    Curr Med Chem; 2014; 21(33):3768-74. PubMed ID: 24934354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development, formulation, and cellular mechanism of a lipophilic copper chelator for the treatment of Wilson's disease.
    Gauthier L; Charbonnier P; Chevallet M; Delangle P; Texier I; Gateau C; Deniaud A
    Int J Pharm; 2021 Nov; 609():121193. PubMed ID: 34673167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chelation therapy in liver diseases of childhood: Current status and response.
    Seetharaman J; Sarma MS
    World J Hepatol; 2021 Nov; 13(11):1552-1567. PubMed ID: 34904029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Specific Copper(II) Chelator TDMQ20 Is Efficient for the Treatment of Wilson's Disease in Mice.
    Zhu Y; Tang Y; Huang L; Nguyen M; Liu Y; Robert A; Meunier B
    Pharmaceutics; 2023 Dec; 15(12):. PubMed ID: 38140060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Liver cirrhosis in primary hemochromatosis and Wilson's disease].
    Kobune M; Kato J; Kohgo Y; Niitsu Y
    Nihon Rinsho; 1994 Jan; 52(1):209-14. PubMed ID: 8114295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron toxicity and chelation therapy.
    Britton RS; Leicester KL; Bacon BR
    Int J Hematol; 2002 Oct; 76(3):219-28. PubMed ID: 12416732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compound overload of copper and iron in patients with Wilson's disease.
    Hayashi H; Yano M; Fujita Y; Wakusawa S
    Med Mol Morphol; 2006 Sep; 39(3):121-6. PubMed ID: 16998622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.